Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 4, 2015, Pages 391-405

  Gisbert, J P ^a   Marin A C ^a   Chaparro, M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ANTIBODY; C REACTIVE PROTEIN; CALGRANULIN; CERTOLIZUMAB PEGOL; HEMOGLOBIN; INFLIXIMAB; METHOTREXATE; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

AGE; COLONOSCOPY; CROHN DISEASE; DISEASE CONTROL; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENETIC MARKER; GESTATIONAL AGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFUSION RELATED REACTION; INTESTINE FLORA; LEUKOCYTE COUNT; MAGNETIC RESONANCE ENTEROGRAPHY; META ANALYSIS; PHENOTYPE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SMOKING; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 85006386593     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13276     Document Type: Review

References (98)

1. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644–59, quiz 660.
2. de Pineton Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15–29.
3. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15: 1295–301.
4. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463–8; quiz e410–461.
5. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862–9.
6. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013; 108: 1268–76.
7. Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis 2014; 8: 31–44.
8. Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012; 18: 174–9.
9. Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease–modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008; 28: 76–87.
10. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Ostergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012; 47: 518–27.
11. Louis E, Belaiche J, Reenaers C. Anti-TNF and Crohn's disease: when should we stop? Curr Drug Targets 2010; 11: 148–51.
12. Gisbert JP, Marín AC, Chaparro M. Risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: a meta-analysis (abstract). J Crohns Colitis 2015; 9(Suppl.1): S315.
13. Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. Clin Gastroenterol Hepatol 2014; 12: 1494–502.
14. Bortlík M, Duricová D, Lukáš M, et al. Infliximab trough levels at treatment discontinuation are associated with increased risk of disease relapse in patients with inflammatory bowel diseases. 20th United European Gastroenterology Week 2012: P0870.
15. Brooks AJ, Sebastian S, Cross SS, et al. Outcome of elective withdrawal of anti-tumour necrosis factor-alpha therapy in patients with Crohn's disease in established remission. J Crohns Colitis 2015; pii: jjv000. [Epub ahead of print]
16. Guidi L, Ratto C, Semeraro S, et al. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol 2008; 12: 111–7.
17. Domenech E, Hinojosa J, Nos P, et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005; 22: 1107–13.
18. Wynands J, Belbouab R, Candon S, et al. 12-month follow-up after successful infliximab therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2008; 46: 293–8.
19. Dart RJ, Griffin N, Taylor K, et al. Reassessment of Crohn's disease treated with at least 12 months of anti-TNF therapy: how likely is treatment withdrawal? Frontline Gastroenterol 2014; 5: 176–82.
20. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63–70 e65; quiz e31.
21. Lu C, Waugh A, Bailey RJ, et al. Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. World J Gastroenterol 2012; 18: 5058–64.
22. Molnar T, Lakatos PL, Farkas K, et al. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013; 37: 225–33.
23. Molander P, Farkkila M, Salminen K, et al. Outcome after discontinuation of TNFalpha-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis 2014; 20: 1021–8.
24. Echarri A, Ollero V, Gallego C, Porta A, Castro J. Anti-TNF withdrawal in IBD patients on deep remission. Risk factors of relapse. 20th United European Gastroenterology Week 2012: P0287.
25. Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata M, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13: 5238–44.
26. Ciria V, Silva P, Leo E, et al. Factors influencing recurrence following suspension of biological treatment. Importance of mucosal healing. J Crohns Colitis 2014; 8(Suppl.1): P487.
27. Chauvin A, Le Thuaut A, Belhassan M, et al. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: a retrospective study. Dig Liver Dis 2014; 46: 695–700.
28. Ramos L, Hernandez A, Carrillo M, Alonso I, Hernandez N, Quintero E. Outcome of treatment with biological agents in Crohn's disease: 117 patients in 5 years from a tertiary referral center. J Crohns Colitis 2014; 8(Suppl. 1): P398.
29. Luppino I, Spagnuolo R, Marasco R, et al. Withdrawal of infliximab (IFX) after achieving remission: outcome in a cohort of inflammatory bowel disease (IBD) patients. Dig Liver Dis 2013; 45S: S100–1.
30. Marino M, Zucchi E, Fabbro M, et al. Outcome of infliximab discontinuation in IBD patients and therapy rechallenging in relapsers: single centre preliminary data. J Crohns Colitis 2014; 8(Suppl. 1): P401.
31. Crombe V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2011; 17: 2144–52.
32. Annunziata ML, Papparella LG, Sansoni I, Balestrieri P, Cicala M. Normalized wall thickness at MRE predicts clinical remission in Crohn's disease after infliximab discontinuation: a 5 years follow-up. J Crohns Colitis 2014; 8(Suppl. 1): P402.
33. Waugh AW, Garg S, Matic K, et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010; 32: 1129–34.
34. Nuti F, Conte F, Cavallari N, et al. Long term efficacy of infliximab in inflammatory bowel disease at a single tertiary center. Dig Liver Dis 2010; 42: S326–7.
35. Farkas K, Lakatos PL, Nagy F, et al. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol 2013; 48: 1394–8.
36. Armuzzi A, Marzo M, Felice C, et al. Long-term scheduled therapy with infliximab in inflammatory bowel disease: a single-centre observational study. Gastroenterology 2010; 238(Suppl. 1): S-691.
37. Muñoz C, Bravo MT, deOrtiz Zárate J, et al. Mucosal healing in patients with ulcerative colitis treated with infliximab. What happens after treatment is discontinued? J Crohns Colitis 2014; 8(Suppl. 1): P405.
38. Dai C, Liu WX, Jiang M, Sun MJ. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS ONE 2014; 9: e110797.
39. Papamichael K, Vande Casteele N, Gils A, et al. Long-term outcome of patients with Crohn's Disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol 2015; 13: 1103–10.
40. Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2014; 40: 338–53.
41. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 27–35.
42. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381–90.
43. Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008; 18: 460–4.
44. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010; 69: 1286–91.
45. Sorrentino D, Nash P, Viladomiu M, Hontecillas R, Bassaganya-Riera J. Stopping anti-TNF agents in patients with crohn's disease in remission: is it a feasible long-term strategy? Inflamm Bowel Dis 2014; 20: 757–66.
46. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430–8.
47. Ternant D, Berkane Z, Picon L, et al. Assessment of the influence of inflammation and FCGR3A genotype on infliximab pharmacokinetics and time to relapse in patients with Crohn's disease. Clin Pharmacokinet 2015; 54: 551–62.
48. Gearry RB, Kamm MA, Hart AL, Bassett P, Gabe SM, Nightingale JM. Predictors for developing intestinal failure in patients with Crohn's disease. J Gastroenterol Hepatol 2013; 28: 801–7.
49. Nunes T, Etchevers MJ, Domenech E, et al. Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther 2013; 38: 752–60.
50. Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis 2014; 8: 717–25.
51. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003; 98: 332–9.
52. Karmiris K, Bielen D, Vanbeckevoort D, et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 2011; 9: 130–6.
53. Castano-Milla C, Chaparro M, Saro C, et al. Effectiveness of Adalimumab in perianal fistulas in Crohn's disease Patients naive to anti-TNF therapy. J Clin Gastroenterol 2015; 49: 34–40.
54. Molnar T, Farkas K, Miheller P, et al. Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease? J Crohns Colitis 2008; 2: 322–6.
55. Shen B. Pouchitis: what every gastroenterologist needs to know. Clin Gastroenterol Hepatol 2013; 11: 1538–49.
56. Viazis N, Giakoumis M, Koukouratos T, et al. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis. J Crohns Colitis 2013; 7: e457–60.
57. Gisbert JP, Gonzalez-Lama Y, Mate J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol 2007; 30: 117–29.
58. de Suray N, Salleron J, Vernier-Massouille G, et al. Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohn's disease patients. A sub-analysis of the STORI study. J Crohns Colitis 2012; 6S1: P274.
59. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009; 41: 56–66.
60. Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut 2013; 62: 1806–16.
61. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894–9.
62. Molander P, Farkkila M, Ristimaki A, et al. Does fecal calprotectin predict short-term relapse after stopping tnfalpha-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis 2015; 9: 33–40.
63. Rajca S, Grondin V, Louis E, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis 2014; 20: 978–86.
64. Chaparro M, Guerra I, Munoz-Linares P, Gisbert JP. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 971–86.
65. Guerra I, Chaparro M, Bermejo F, Gisbert JP. Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease. Curr Drug Metab 2014; 15: 875–81.
66. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014; 13: 24–30.
67. Armuzzi A, Van Assche G, Reinisch W, et al. Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. J Crohns Colitis 2012; 6: 492–502.
68. Farkas K, Lakatos PL, Szucs M, et al. Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy. World J Gastroenterol 2014; 20: 2995–3001.
69. Rismo R, Olsen T, Cui G, et al. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease. Scand J Gastroenterol 2013; 48: 311–9.
70. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9.
71. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52–65.
72. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760–7.
73. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987–95.
74. Danese S, Fiorino G, Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther 2011; 34: 1–10.
75. Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis 2013; 7: 154–60.
76. Karmiris K, Noman M, Vermeire S, van Assche G, Rutgeerts P. Dose de-escalation in patients with inflammatory bowel disease treated long-term with adalimumab 40 mg weekly. Gut 2008; 57(Suppl. III): A255.
77. Chaparro M, Barreiro-de Acosta M, Garcia-Planella E, et al. Effectiveness of a dose “de-escalation” strategy with anti-TNF drugs in patients with Crohn's disease. J Crohns Colitis 2011; 5: S103.
78. Sebastian S, Robinson K, Warren L, et al. Outcomes after elective withdrawal of anti-TNF therapy in Crohn's disease: a multicentre study. J Crohns Colitis 2013; 7(Suppl. 1):S166–7.
79. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25: 665–72.
80. Regueiro M. Management and prevention of postoperative Crohn's disease. Inflamm Bowel Dis 2009; 15: 1583–90.
81. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441–50 e441; quiz 716.
82. Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010; 8: 591–9 e591; quiz e578-599.
83. van Lent AU, D'Haens GR. Management of postoperative recurrence of Crohn's disease. Dig Dis 2013; 31: 222–8.
84. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 1426–38.
85. Chaparro M, Gisbert JP. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr Pharm Biotechnol 2011; 12: 765–73.
86. Chaparro M, Gisbert JP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? Expert Opin Drug Saf 2014; 13: 1749–62.
87. Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013; 11: 318–21.
88. de Lima A, Zelinkova Z, der van Ent C, der van Woude CJ. Anti-TNF is safe to stop in the second trimester of pregnancy in IBD women in remission. Gastroenterology 2014; 146(Suppl. 1): 340.
89. Theede K, Dahlerup JF, Fallingborg J, et al. Biologic therapy in inflammatory bowel disease. Dan Med J 2013; 60: B4652.
90. Anon. NICE Technology Appraisal Guidance 187: infliximab (review) and adalimumab for the treatment of Crohn's disease. National Institute for Health and Clinical Excellence, 2010. Available at: http://guidance.nice.org.uk/TA187.
91. Blackmore L, Harris A. A prospective study of infliximab withdrawal after 12 months of treatment in patients with Crohn's disease: how will NICE guidance affect patient care? Clin Med 2012; 12: 235–8.
92. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199–212; quiz 213.
93. Pittet V, Froehlich F, Maillard MH, et al. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. J Crohns Colitis 2013; 7: 820–6.
94. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917–24.
95. Felice C, Pugliese D, Guidi L, et al. Retreatment with infliximab in inflammatory bowel disease: tolerability and effectiveness of different re-induction regimens.J Crohns Colitis 2014; 8(Suppl.1): P363.
96. Eshuis EJ, Peters CP, van Bodegraven AA, et al. Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis 2013; 19: 1622–30.
97. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol 2014; 12: 1474–81 e1472; quiz e1491.
98. Domenech E, Zabana Y, Manosa M, Garcia-Planella E, Cabre E, Gassull MA. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. J Clin Gastroenterol 2010; 44: 34–7.